On February 12, Marcelo Bigal, Teva Pharmaceutical Industries, Frazer, Pennsylvania, US, gave a talk on CGRP as a target for prevention of migraine, with a focus on anti-CGRP antibodies in clinical development. After his talk, there was a panel discussion featuring:
- Rami Burstein, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, US
- Andrew Russo, University of Iowa, Iowa City, US
- Stephen Silberstein, Thomas Jefferson University, Philadelphia, US
- Greg Dussor, University of Texas at Dallas, US (moderator)
Watch the webinar recording below (for best viewing enter full screen mode).
This is how Bigal describes his talk:
Calcitonin gene-related peptide (CGRP) is an extensively studied neuropeptide that has been implicated in the pathophysiology of migraine. While a number of small molecule antagonists against the CGRP receptor have demonstrated that targeting this pathway is a valid and effective way of treating migraine, off-target hepatoxicity and formulation issues have hampered the development for regulatory approval of any therapeutic in this class. The development of monoclonal antibodies to CGRP or its receptor as therapeutic agents has allowed this pathway to be reinvestigated. In this webinar, I will review why CGRP is an ideal target for the prevention of migraine and describe four monoclonal antibodies against either CGRP or its receptor that are in clinical development for the treatment of both episodic and chronic migraine. I will describe what has been publicly disclosed about clinical trials of anti-CGRP therapy and future clinical development plans.
“Targeting Calcitonin Gene-Related Peptide (CGRP) for Prevention of Migraine” is the fifth in a new series of PRF webinars supported by Genentech and MedImmune, with additional site support from other PRF sponsors. All webinars and other site content on PRF are editorially independent; all editorial decisions are made solely by the PRF editors. See previous PRF webinars here.